

MT2019-06: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.

Status: Recruiting

[Eligibility Criteria](#)

[Conditions & Interventions](#)

[More Information](#)

Description: Evaluate the efficacy of treatment with bb1111 (also known as LentiGlobin BB305 Drug Product for Sickle Cell Disease) in subjects with sickle cell disease (SCD).

Contact(s): Danielle Jin - zhuxx003@umn.edu

Principal Investigator: Ashish Gupta

IRB

Number: STUDY00006923

System ID: 25197

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.